Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Documentation
Home
>
Investors & media
>
Documentation
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
Documentation type
All
General Assembly
Financial statements and reports
Regulated information
Corporate presentations
General meetings
22 December 2023
General meetings
Shares and voting rights statement – December 6, 2023
Open in new window
22 December 2023
General meetings
Statutory Auditors’ report – Resolutions 1 to 5
Open in new window
06 December 2023
General meetings
Preliminary notice – EGM January 10, 2024
Open in new window
22 November 2023
Regulated information
2022 Universal Registration Document Amendment – November 2023
Open in new window
22 November 2023
Regulated information
Securities Note – November 2023
Open in new window
04 October 2023
Corporate presentations
CORPORATE PRESENTATION – OCTOBER 2023
Open in new window
18 September 2023
Financial statements and reports
2023 HALF-YEAR FINANCIAL REPORT
Open in new window
11 September 2023
Corporate presentations
CORPORATE PRESENTATION – SEPTEMBER 2023
Open in new window
22 June 2023
General Assembly, General meetings
GenSight Biologics Resultats AGM 21 juin 2023
Open in new window
22 June 2023
General Assembly, General meetings
GenSight Biologics – 2023 Compensation Policies
Open in new window
View previous 9 articles
1
2
3
4
5
6
7
8
9
10
…
21
View next 9 articles
Go back to the page of the page